Novo Nordisk is working on long-acting GLP-1 agents

Novo Nordisk hopes that this development will lead to obesity medication only needing to be taken once a month, every three months or once a year in the future. 
Photo: Novo Nordisk
Photo: Novo Nordisk

Novo Nordisk is developing a new obesity candidate that may only need to be taken once a year, according to Danish newspaper Berlingske.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading